Explore

Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility

Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility

Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase
Trendline Trendline
AI in Biotechnology: Transforming Drug Discovery and Personalized Medicine

AI in Biotechnology: Transforming Drug Discovery and Personalized Medicine

AI in Biotechnology: Transforming Drug Discovery and Personalized Medicine
Trendline Trendline
Palatin Technologies to List on Nasdaq, Enhancing Market Visibility

Palatin Technologies to List on Nasdaq, Enhancing Market Visibility

Palatin Technologies to List on Nasdaq, Enhancing Market Visibility
Trendline Trendline
GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting
Trendline Trendline
Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage
Trendline Trendline
Atisama Therapeutics Progresses RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Progresses RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Progresses RB042 in Phase 1 Trial and Appoints New Board Chair